Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMP-131R10 in Advanced Solid Tumors and Metastatic Colorectal Cancer
NCT02482441Phase 1Completed
- Sponsor
- OncoMed Pharmaceuticals
- Start
- Jul 2015
- Primary completion
- Jan 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of rosmantuzumab in solid tumor and colorectal cancer (CRC) (2 arms), sponsored by OncoMed Pharmaceuticals. Primary endpoint: Incidence of Dose Limiting Toxicities at 28 days. Started Jul 2015; status: completed.
02
Drugs
rosmantuzumab
03
Conditions
solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02482441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02482441.